PCSK9 and metabolic syndrome: Bioactive peptides have emerged as a promising therapeutic class for dyslipidemia and residual cardiovascular risk, operating through mechanisms that include apolipoprotein mimicry, PCSK9 inhibition, and modulation of cholesterol absorption and inflammation, yet translational success remains constrained by poor pharmacokinetics, limited oral bioavailability, and inconsistent clinical outcomes.